FDA imposes partial hold on BioNTech-OncoC4's Phase III trial for Non-Small Cell Lung Cancer due to varying patient results.
Read more
LaNova Medicines initiates Phase 1 trial for LM-299, an anti-PD-1/VEGF bispecific antibody, and completes $42M Series C1 financing to advance its oncology pipeline.
Read more
George Medicines' GMRx2 triple combination pill shows superior efficacy and safety in Phase III trial for Hypertension, published in The Lancet.
Read more
Nurix Therapeutics' BTK degrader NX-5948 shows 77.8% response rate in Phase 1 trial for relapsed/refractory Waldenstrom’s Macroglobulinemia.
Read more
Can-Fite's Piclidenoson shows significant efficacy in canine Osteoarthritis study, leading to a $325M licensing deal with Vetbiolix.
Read more
EMA's CHMP recommends Novo Nordisk's hemophilia therapy and Ionis-AstraZeneca's TTR therapy for approval.
Read more
Supernus Pharmaceuticals' SPN-820 shows rapid improvement in Major Depressive Disorder in Phase 2a trial, with plans for Phase 2b data in Treatment-Resistant Depression next year.
Read more
Cofactor Genomics' OncoPrism receives Medicare coverage for predicting immunotherapy response in head and neck squamous cell carcinoma.
Read more
Novartis' Kisqali receives positive CHMP opinion for reducing recurrence risk in HR+/HER2- early breast cancer.
Read more
FDA approves BOTOX® Cosmetic for temporary improvement of moderate to severe platysma bands, expanding its aesthetic indications.
Read more
Accord Healthcare's ustekinumab biosimilar, Imuldosa®, receives positive CHMP opinion for immunology conditions.
Read more
Roche's VENTANA CLDN18 RxDx Assay receives FDA approval as the first companion diagnostic for gastric and gastroesophageal junction cancer, enabling targeted treatment with VYLOY.
Read more
FibroBiologics partners with Charles River to manufacture fibroblast cell therapies for Diabetic Foot Ulcer clinical trial in 2025.
Read more
ITM and NTP renew technology license and sign a new agreement to boost global production of Lutetium-177 for cancer treatment.
Read more
Legacy and Posterity Health partner to enhance access to male fertility care through a hybrid model offering at-home testing and telehealth services.
Read more
US Heart & Vascular partners with Birmingham Heart Clinic to enhance cardiovascular care in Alabama.
Read more
REGiMMUNE and Kiji Therapeutics merge to form a leading Treg biotech, planning IPO by 2025.
Read more
Advanced Care Group expands nationwide by acquiring 3D Medical Staffing and integrating AI-powered recruiting solutions.
Read more
Avantor completes $650 million divestiture of its clinical services business to Audax Private Equity, focusing on strategic growth in lab and production sectors.
Read more
Audax Private Equity acquires Avantor's clinical services, rebrands as Resonant Clinical Solutions to enhance clinical trial services.
Read more
KdT Ventures secures over $100M for life sciences investments; Terray raises $120M in Series B funding.
Read more
Bright Minds Biosciences announces a US$35 million private placement to fund neurological and psychiatric drug development.
Read more
ARTHEx Biotech doses first patient in Phase I-IIa trial of ATX-01 for Myotonic Dystrophy Type 1, a novel anti-microRNA therapeutic.
Read more
Inventiva secures €348M for late-stage lanifibranor trials in Metabolic Dysfunction-Associated Steatohepatitis.
Read more
KFSHRC leads in cancer treatment with CAR-T cell therapy and CRISPR, achieving a 90% recovery rate for leukemia.
Read more
